美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Bioxytran, Inc.

0.0320

-0.0042-11.60%

成交量：77.86萬

成交額：2.71萬

市值：317.13萬

市盈率：-1.34

高：0.0380

開：0.0362

低：0.0310

收：0.0362

52周最高：0.2283

52周最低：0.0262

股本：9,910.39萬

流通股本：9,860.39萬

量比：0.44

換手率：0.79%

股息：- -

股息率：- -

每股收益(TTM):-0.0239

每股收益(LYR):-0.0379

淨資產收益率：--

總資產收益率：-687.83%

市淨率：-1.08

市盈率(LYR):-0.84

資料載入中...

總覽公司新聞資訊公告

Bioxytran宣佈Prolectin-M劑量優化取得積極成果，向三期註冊試驗邁進

Bioxytran Inc公布SEC文件：試驗期間未報告嚴重不良事件，無治療相關中止案例

Bioxytran公司公布廣譜抗病毒藥物Prolectin-M針對輕中度新冠患者的1B/2a期臨床研究積極結果

Bioxytran公布積極二期結果：Prolectin-Mbioxytran實現快速病毒清除

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BIXT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIXT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","market":"US","secType":"STK","nameCN":"Bioxytran, Inc.","latestPrice":0.032,"timestamp":1774035420000,"preClose":0.0362,"halted":0,"volume":778580,"delay":15,"changeRate":-0.11602209944751386,"floatShares":98603900,"shares":99103900,"eps":-0.0239,"marketStatus":"交易中","change":-0.0042,"latestTime":"03-20 15:37:00 EDT 延時","open":0.0362,"high":0.038,"low":0.031,"amount":27130.3870013,"amplitude":0.19337,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.0239,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.0362,"volumeRatio":0.442692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","floatShares":98603900,"roa":"-687.83%","roe":"--","lyrEps":-0.037945,"volumeRatio":0.442692,"shares":99103900,"dividePrice":0,"high":0.038,"amplitude":0.19337,"preClose":0.0362,"low":0.031,"week52Low":0.0262,"pbRate":"-1.08","week52High":0.2283,"institutionHeld":0,"latestPrice":0.032,"eps":-0.0239,"divideRate":0,"volume":778580,"delay":15,"ttmEps":-0.0239,"open":0.0362,"prevYearClose":0.0758,"prevWeekClose":0.0313,"prevMonthClose":0.045,"prevQuarterClose":0.0758,"fiveDayClose":0.0313,"twentyDayClose":0.0449,"sixtyDayClose":0.077},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIXT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIXT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIXT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIXT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1173660975","title":"Bioxytran宣佈Prolectin-M劑量優化取得積極成果，向三期註冊試驗邁進","url":"https://stock-news.laohu8.com/highlight/detail?id=1173660975","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173660975?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 04:41","pubTimestamp":1772656876,"startTime":"0","endTime":"0","summary":"生物制药公司Bioxytran, Inc.近日宣布，其在研药物Prolectin-M的剂量优化研究取得积极进展。这一关键性突破为推进该药物的三期注册临床试验奠定了重要基础。\n研究数据显示，通过系统化的剂量探索，Prolectin-M在疗效与安全性之间达到了理想平衡。这一成果不仅验证了前期临床数据，更为后续大规模试验的设计提供了科学依据。\n公司计划基于现有数据，加速启动三期临床试验的筹备工作。若后续试验顺利推进，Prolectin-M有望成为针对相关适应症的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0},{"id":"1186486850","title":"Bioxytran Inc公布SEC文件：試驗期間未報告嚴重不良事件，無治療相關中止案例","url":"https://stock-news.laohu8.com/highlight/detail?id=1186486850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186486850?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 22:27","pubTimestamp":1772461635,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会（SEC）的文件显示，生物制药公司Bioxytran, Inc.在其临床研究过程中取得了积极的安全性数据。文件明确指出，该试验未出现任何严重不良事件的报告，同时所有受试者均完成了既定治疗方案，未发生因治疗原因导致的中断情况。\n这一结果凸显了该公司在研疗法的耐受性表现，为后续临床推进提供了关键安全性依据。在当前生物科技领域高度关注药物安全性的背景下，此类数据无疑增强了投资者对研发进程的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"1175660458","title":"Bioxytran公司公布廣譜抗病毒藥物Prolectin-M針對輕中度新冠患者的1B/2a期臨床研究積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1175660458","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175660458?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 22:26","pubTimestamp":1772461614,"startTime":"0","endTime":"0","summary":"生物制药企业Bioxytran公司近日宣布，其研发的广谱抗病毒药物Prolectin-M在针对轻中度新冠肺炎患者的1B/2a期临床试验中取得突破性进展。该研究数据显示，受试者在用药后病毒载量显著降低，且未出现严重不良反应，标志着这款基于糖工程技术的创新疗法在应对新冠病毒及其他包膜病毒方面展现出巨大潜力。\n研究人员指出，Prolectin-M通过阻断病毒与宿主细胞受体的结合机制发挥作用，这种独特的作用路径使其具备应对多种变异毒株的广谱抗病毒特性。此次临床试验结果将为后续更大规模的二期研究奠定坚实基础，也为全球抗病毒药物研发领域注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0},{"id":"1102628117","title":"Bioxytran公布積極二期結果：Prolectin-Mbioxytran實現快速病毒清除","url":"https://stock-news.laohu8.com/highlight/detail?id=1102628117","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102628117?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 19:02","pubTimestamp":1770807750,"startTime":"0","endTime":"0","summary":"Bioxytran, Inc. (简称Bioxytran) 近日公布了其二期临床试验的积极数据。结果显示，其研发的药物Prolectin-Mbioxytran在试验中展现出能够快速清除病毒的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}